Merck & Co., Inc. And Samsung Bioepis Enter Collaboration Agreement To Develop And Commercialize Insulin Glargine Candidate For Diabetes
Published: Feb 10, 2014
WHITEHOUSE STATION, N.J. & SEOUL, SOUTH KOREA--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Samsung Bioepis Co., Ltd., announced today that they have expanded their collaboration with an agreement to develop, manufacture and commercialize MK-1293, an insulin glargine candidate for the treatment of patients with type 1 and type 2 diabetes. Phase III clinical studies in type 1 and type 2 diabetes will begin soon.
Help employers find you! Check out all the jobs and post your resume.